Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results